Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
News|Articles|March 12, 2009
Bevasiranib trial for wet-AMD discontinued
OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).
Advertisement
OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).
An analysis of the preliminary data conducted by an independent data monitoring committee demonstrated that the trial was unlikely to meet its primary end point (improvement in visual acuity), although bevasiranib used adjunctively with ranibizumab (Lucentis, Genentech) did show activity in this disease state.
No systemic safety issues were identified in the trial.
Advertisement
Related to this article
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.
A truly transparent PBM arrangement starts with full disclosure of direct and indirect compensation.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
2
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
3
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
4
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
5